Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
3(25%)
Results Posted
14%(1 trials)

Phase Distribution

Ph phase_1
2
17%
Ph not_applicable
6
50%
Ph phase_2
2
17%
Ph phase_4
2
17%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
6(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(3)
Completed(7)
Terminated(2)

Detailed Status

Completed7
Active, not recruiting2
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 22 (16.7%)
Phase 42 (16.7%)
N/A6 (50.0%)

Trials by Status

active_not_recruiting217%
recruiting18%
completed758%
withdrawn217%

Recent Activity

3 active trials
Showing 5 of 12
recruitingphase_2

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

NCT06142656
withdrawnphase_1

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

NCT04410341
withdrawnphase_2

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

NCT04761861
active_not_recruitingnot_applicable

Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes

NCT06913101
active_not_recruitingnot_applicable

Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes

NCT06889909
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06142656Phase 2

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

Recruiting
NCT04410341Phase 1

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

Withdrawn
NCT04761861Phase 2

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Withdrawn
NCT06913101Not Applicable

Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes

Active Not Recruiting
NCT06889909Not Applicable

Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes

Active Not Recruiting
NCT06068686Not Applicable

Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

Completed
NCT06313008Not Applicable

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Completed
NCT05329844Not Applicable

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.

Completed
NCT04916093Phase 4

Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes

Completed
NCT03500900Not Applicable

Vildagliptin on Gastric Accommodation

Completed
NCT03253562Phase 4

Metformin Versus Vildagliptin for Diabetic Hypertensive Patients

Completed
NCT01582308Phase 1

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12